Physician profile
David G Carpenter
NPI 1225130743
$3,219.25
in general payments reported to CMS, 2019-2025
36 companies · $34.43 in 2025
The $34.43 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,170 · 2020: $412 · 2021: $836 · 2022: $405 · 2023: $316 · 2024: $46.70 · 2025: $34.43.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $397.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $397.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $561.07 | 2019-2023 | Assurity |
| Janssen Pharmaceuticals, INC | $456.55 | 2019-2021 | |
| Vertiflex, INC. | $207.58 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $173.12 | 2019-2022 | |
| Bard Peripheral Vascular, INC. | $151.17 | 2021 | |
| Biotronik INC. | $144.70 | 2019 | |
| Pfizer INC. | $135.98 | 2019-2023 | |
| Glaxosmithkline, LLC. | $135.29 | 2020-2022 | |
| Amarin Pharma, INC. | $134.93 | 2019-2022 | |
| Medtronic Vascular, INC. | $104.56 | 2020 | |
| Novo Nordisk INC | $98.79 | 2019-2020 | |
| Abbvie INC. | $98.65 | 2021-2023 | Ubrelvy |
| Merck Sharp & Dohme LLC | $93.18 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $92.46 | 2022 | |
| Lilly USA, LLC | $78.90 | 2021-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $77.39 | 2021-2025 | Airsupra |
| Antares Pharma, INC. | $59.70 | 2019-2022 | |
| Sanofi Pasteur INC. | $52.50 | 2019 | |
| Sanofi-Aventis U.S. LLC | $34.36 | 2019-2022 | |
| Lundbeck LLC | $32.33 | 2023 | Rexulti |
| Allergan, INC. | $28.97 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.01 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $23.54 | 2023 | Camzyos |
| Novartis Pharmaceuticals Corporation | $23.33 | 2022 | |
| Genentech USA, INC. | $20.83 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $20.65 | 2021 | |
| Medtronic, INC. | $19.00 | 2025 | Inceptiv |
| Biogen, INC. | $16.10 | 2020 | |
| Avanir Pharmaceuticals, INC. | $15.90 | 2021 | |
| Optinose US, INC. | $15.59 | 2020 | |
| Astellas Pharma US INC | $14.93 | 2019 | |
| Tactile Systems Technology INC | $14.66 | 2019 | |
| Currax Pharmaceuticals LLC | $14.45 | 2019 | |
| Linus Health, INC. | $13.99 | 2023 | |
| Philips North America LLC | $13.71 | 2022 | |
| Horizon Therapeutics Plc | $12.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Carpenter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.